Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

M-065

Supelco

(±)-MDEA solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Synonym(s):

(±)-3,4-Methylenedioxyethylamphetamine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C12H17NO2
CAS Number:
82801-81-8
Molecular Weight:
207.27
EC Number:
200-659-6
MDL number:
MFCD00871703
UNSPSC Code:
41116107
PubChem Substance ID:
329817819
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule D (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

2-8°C

SMILES string

CC(CC1=CC=C(OCO2)C2=C1)NCC

InChI

1S/C12H17NO2/c1-3-13-9(2)6-10-4-5-11-12(7-10)15-8-14-11/h4-5,7,9,13H,3,6,8H2,1-2H3

InChI key

PVXVWWANJIWJOO-UHFFFAOYSA-N

Related Categories

General description

MDEA is an illicit recreational drug of the amphetamine and phenethylamine classes. This analytical reference standard is suitable to use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis, or urine drug testing. A 3,4-methylenedioxy derivative of N-ethylamphetamine, MDEA is abused for its psychedelic effects, similar to those of its structural analog MDMA (Ecstasy).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

A-050

Amine Mixture-6 solution, 250 μg/mL each component in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-010

(±)-MDA-D5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-011

(±)-MDMA-D5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-012

(±)-MDA solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-013

(±)-MDMA solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-027

(±)-MDA-D5 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-029

(±)-MDMA-D5 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-067

(±)-MDEA-D5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-068

(±)-MDEA-D5 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-081

(±)-MDEA-D6 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-082

(±)-MDEA-D6 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-144

MDAI hydrochloride solution, 100 μg/mL in acetonitrile: water (9:1) with 5% 1 M HCl (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

EU REACH Annex XVII (Restriction List)

CAS No.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tsadik T Abraham et al.
Journal of analytical toxicology, 33(8), 439-446 (2009-10-31)
3,4-Methylenedioxymethamphetamine (MDMA), or ecstasy, is excreted as unchanged drug, 3,4-methylenedioxyamphetamine (MDA), and free and glucuronidated/sulfated 4-hydroxy-3-methoxymethamphetamine (HMMA), and 4-hydroxy-3-methoxyamphetamine (HMA) metabolites. The aim of this paper is to describe the pattern and timeframe of excretion of MDMA and its metabolites
Rita Santos et al.
Journal of chemical information and modeling, 50(1), 146-154 (2009-11-11)
Active-site water molecules form an important component in biological systems, facilitating promiscuous binding or an increase in specificity and affinity. Taking water molecules into account in computational approaches to drug design or site-of-metabolism predictions is currently far from straightforward. In
Markus R Meyer et al.
Drug metabolism and disposition: the biological fate of chemicals, 37(6), 1152-1156 (2009-03-21)
The 3,4-methylenedioxy-methamphetamine (MDMA)-related designer drug 3,4-methylenedioxyethylamphetamine (MDEA, Eve) is a chiral compound that is mainly metabolized by N-deethylation and demethylenation during phase I metabolism. The involvement of several cytochrome P450 (P450) isozymes in these metabolic steps has been demonstrated by
Peter R Stout et al.
Journal of analytical toxicology, 34(8), 430-443 (2010-01-01)
On November 25, 2008, the U.S. Department of Health and Human Services posted a final notice in the Federal Register authorizing the use of liquid chromatography-tandem mass spectrometry (LC-MS-MS) and other technologies in federally regulated workplace drug testing (WPDT) programs.
Kei Zaitsu et al.
Forensic science international, 188(1-3), 131-139 (2009-05-02)
This is the first report on identifying the specific metabolites of the new designer drugs 2-methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (bk-MBDB) and 2-ethylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (bk-MDEA) in human urine using synthesized standards. Based on GC/MS and LC/MS, we identified N-dealkylation, demethylenation followed by O-methylation, and beta-ketone
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service